Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2012

View Archived Issues

Cortical thickness-based biomarker may predict cognitive decline in cognitively normal adults

New HCV NS5B inhibitors synthesized by Arrow Therapeutics and AstraZeneca

Prana receives FDA clearance to initiate study of PBT-2

Presurgical trial set to investigate MK-2206 in operable invasive cancer

University of Arizona scientists assess natural monoterpene in phase I trial

Dosing of VT-464 begins in phase I/II study

Epigenomics submits PMA filing for Epi proColon

FDA accepts Repros Therapeutics' IND for Proellex-V

Phase I/II study evaluates rintatolimod as adjuvant for HER2 vaccine

New class of tetracyclic benzothiazepines identified as promising antimalarial agents

Gilead Sciences discloses new HCV replication inhibitors

Novel NS5B inhibitors patented by Biota Scientific Management

Afraxis researchers prepare new serine/threonine-protein kinase PAK inhibitors

Profectus BioSciences begins immunization with HIV vaccine in phase I trial

Novel beta-secretase 1 inhibitors claimed by Janssen Pharmaceutica

Novel protein-tyrosine kinase inhibitors synthesized in China

AstraZeneca reports novel dipeptidyl peptidase 1 inhibitors

Oncodesign and Ipsen enter research collaboration on Parkinson's disease

Ironwood Pharmaceuticals and Bionomics collaborate on anxiolytics

Basilea Pharmaceutica to file for approval of two products this year

Data safety monitoring board reports no safety concerns for phase IIb eteplirsen trial

First patient vaccinated in study of DPX-Survivac cancer vaccine

NeuroGenetic Pharmaceuticals receives funds to support development of gamma-secretase modulator

ProFibrix's U.S. phase II study of Fibrocaps meets all endpoints

Circadian Technologies initiates first clinical study of VGX-100

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...